These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 22993152)

  • 1. Neutralizing capacity of monoclonal antibodies that recognize peptide sequences underlying the carbohydrates on gp41 of simian immunodeficiency virus.
    Martinez-Navio JM; Desrosiers RC
    J Virol; 2012 Dec; 86(23):12484-93. PubMed ID: 22993152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycosylation of gp41 of simian immunodeficiency virus shields epitopes that can be targets for neutralizing antibodies.
    Yuste E; Bixby J; Lifson J; Sato S; Johnson W; Desrosiers R
    J Virol; 2008 Dec; 82(24):12472-86. PubMed ID: 18829751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma.
    Yuste E; Sanford HB; Carmody J; Bixby J; Little S; Zwick MB; Greenough T; Burton DR; Richman DD; Desrosiers RC; Johnson WE
    J Virol; 2006 Mar; 80(6):3030-41. PubMed ID: 16501112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Truncating the gp41 Cytoplasmic Tail of Simian Immunodeficiency Virus Decreases Sensitivity to Neutralizing Antibodies without Increasing the Envelope Content of Virions.
    White E; Wu F; Chertova E; Bess J; Roser JD; Lifson JD; Hirsch VM
    J Virol; 2018 Feb; 92(3):. PubMed ID: 29142124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simian immunodeficiency virus mutants resistant to serum neutralization arise during persistent infection of rhesus monkeys.
    Burns DP; Collignon C; Desrosiers RC
    J Virol; 1993 Jul; 67(7):4104-13. PubMed ID: 8510218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence against extracellular exposure of a highly immunogenic region in the C-terminal domain of the simian immunodeficiency virus gp41 transmembrane protein.
    Postler TS; Martinez-Navio JM; Yuste E; Desrosiers RC
    J Virol; 2012 Jan; 86(2):1145-57. PubMed ID: 22072749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities.
    Johnson WE; Sanford H; Schwall L; Burton DR; Parren PW; Robinson JE; Desrosiers RC
    J Virol; 2003 Sep; 77(18):9993-10003. PubMed ID: 12941910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization and Implementation of a Diverse Simian Immunodeficiency Virus SIVsm Envelope Panel in the Assessment of Neutralizing Antibody Breadth Elicited in Rhesus Macaques by Multimodal Vaccines Expressing the SIVmac239 Envelope.
    Kilgore KM; Murphy MK; Burton SL; Wetzel KS; Smith SA; Xiao P; Reddy S; Francella N; Sodora DL; Silvestri G; Cole KS; Villinger F; Robinson JE; Pulendran B; Hunter E; Collman RG; Amara RR; Derdeyn CA
    J Virol; 2015 Aug; 89(16):8130-51. PubMed ID: 26018167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breakthrough of SIV strain smE660 challenge in SIV strain mac239-vaccinated rhesus macaques despite potent autologous neutralizing antibody responses.
    Burton SL; Kilgore KM; Smith SA; Reddy S; Hunter E; Robinson HL; Silvestri G; Amara RR; Derdeyn CA
    Proc Natl Acad Sci U S A; 2015 Aug; 112(34):10780-5. PubMed ID: 26261312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques.
    Ourmanov I; Bilska M; Hirsch VM; Montefiori DC
    J Virol; 2000 Mar; 74(6):2960-5. PubMed ID: 10684319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies.
    Chackerian B; Rudensey LM; Overbaugh J
    J Virol; 1997 Oct; 71(10):7719-27. PubMed ID: 9311856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Envelope variable region 4 is the first target of neutralizing antibodies in early simian immunodeficiency virus mac251 infection of rhesus monkeys.
    Yeh WW; Brassard LM; Miller CA; Basavapathruni A; Zhang J; Rao SS; Nabel GJ; Mascola JR; Letvin NL; Seaman MS
    J Virol; 2012 Jul; 86(13):7052-9. PubMed ID: 22532675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of neutralization epitopes of simian immunodeficiency virus (SIV) recognized by rhesus monoclonal antibodies derived from monkeys infected with an attenuated SIV strain.
    Cole KS; Alvarez M; Elliott DH; Lam H; Martin E; Chau T; Micken K; Rowles JL; Clements JE; Murphey-Corb M; Montelaro RC; Robinson JE
    Virology; 2001 Nov; 290(1):59-73. PubMed ID: 11883006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strain-specific neutralizing determinant in the transmembrane protein of simian immunodeficiency virus.
    Kodama T; Burns DP; Silva DP; Veronese FD; Desrosiers RC
    J Virol; 1991 Apr; 65(4):2010-8. PubMed ID: 1705994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SOSIP Trimer-Specific Antibodies Isolated from a Simian-Human Immunodeficiency Virus-Infected Monkey with versus without a Pre-blocking Step with gp41.
    Duggan NN; Weisgrau KL; Magnani DM; Rakasz EG; Desrosiers RC; Martinez-Navio JM
    J Virol; 2022 Jan; 96(2):e0158221. PubMed ID: 34730398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-Specific Monoclonal Antibodies.
    von Bredow B; Arias JF; Heyer LN; Moldt B; Le K; Robinson JE; Zolla-Pazner S; Burton DR; Evans DT
    J Virol; 2016 Jul; 90(13):6127-6139. PubMed ID: 27122574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells.
    Quinnan GV; Yu XF; Lewis MG; Zhang PF; Sutter G; Silvera P; Dong M; Choudhary A; Sarkis PT; Bouma P; Zhang Z; Montefiori DC; Vancott TC; Broder CC
    J Virol; 2005 Mar; 79(6):3358-69. PubMed ID: 15731230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection.
    Derby NR; Kraft Z; Kan E; Crooks ET; Barnett SW; Srivastava IK; Binley JM; Stamatatos L
    J Virol; 2006 Sep; 80(17):8745-62. PubMed ID: 16912322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of glycosylation on antigenicity of simian immunodeficiency virus SIV239: induction of rapid V1/V2-specific non-neutralizing antibody and delayed neutralizing antibody following infection with an attenuated deglycosylated mutant.
    Sugimoto C; Nakayama EE; Shioda T; Villinger F; Ansari AA; Yamamoto N; Suzuki Y; Nagai Y; Mori K
    J Gen Virol; 2008 Feb; 89(Pt 2):554-566. PubMed ID: 18198387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of HIV neutralizing antibodies against the MPER of the HIV envelope protein by HA/gp41 chimeric protein-based DNA and VLP vaccines.
    Ye L; Wen Z; Dong K; Wang X; Bu Z; Zhang H; Compans RW; Yang C
    PLoS One; 2011; 6(5):e14813. PubMed ID: 21625584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.